Vantage logo

Go or no go? A first for Nefecon

Calliditas is hoping for its first approval, while Abbvie is gearing up to enter the crowded migraine space with an oral anti-CGRP project.

Vantage logo

Go or no go? The FDA plays hardball

April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.